BioInvent to Host Virtual Event on Efficacy Data for BI-1808 and BI-1206

BioInvent International AB, a prominent biotech firm specializing in cancer immunotherapy, announced its upcoming virtual Key Opinion Leader (KOL) event on June 18, 2024. The event, scheduled from 9:00-10:45 AM ET/3-4:45 PM CEST, aims to delve into the recent clinical data for their leading antibodies, BI-1808 and BI-1206, which will be detailed at upcoming ASCO and EHA conferences.

The event will feature Dr. Alexander Eggermont, a distinguished expert in surgical oncology and immunotherapy, who will join BioInvent's management team in discussing the promising clinical outcomes associated with BioInvent's two primary antibodies. BI-1808 and BI-1206 represent the forefront of BioInvent's extensive pipeline targeting novel immunomodulatory treatments for various cancers.

BI-1808 is an anti-TNFR2 antibody that has exhibited significant efficacy as a single agent in an ongoing Phase 1/2a trial, as well as in combination with pembrolizumab for patients with advanced cancers. Meanwhile, BI-1206, an anti-FcyRIIB antibody, is under evaluation in two separate Phase 1/2a trials. One trial focuses on its combination with rituximab for non-Hodgkin's lymphoma (NHL) patients, while the other investigates its use alongside pembrolizumab for patients with solid tumors. The recent data reveal that BI-1206 has sustained therapeutic responses in patients who have undergone extensive prior treatments.

The virtual event will provide a comprehensive overview of BioInvent's development strategy and forecast significant upcoming announcements for 2024. Following the formal presentation, there will be a live Q&A session, allowing attendees to engage directly with the speakers.

Dr. Alexander Eggermont, who will be a key speaker, is globally recognized for his expertise in surgical oncology, immunotherapy, and cancer drug development. He currently holds several notable positions, including Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology and Professor of Immunotherapy at the University Medical Center Utrecht in the Netherlands. Additionally, he serves as Professor of Oncology at Paris-Saclay University in France and is involved with the Comprehensive Cancer Center Program for Deutsche KrebsHilfe and the German Cancer Consortium (DKFZ).

Dr. Eggermont's illustrious career includes his previous role as Director General of Gustave Roussy Comprehensive Cancer Center in France and multiple professorships at renowned institutions. He has also held leadership positions in major cancer organizations, such as President of ECCO and EORTC, and has been a board member of ASCO. As an accomplished researcher, Dr. Eggermont has published over 1,000 peer-reviewed papers and received numerous professional accolades.

BioInvent International AB is a clinical-stage biotechnology company dedicated to discovering and developing innovative immunomodulatory antibodies for cancer therapy. The company is currently progressing with five drug candidates across six ongoing clinical programs, targeting both hematological cancers and solid tumors. Their proprietary F.I.R.S.T™ technology platform enables the identification of novel targets and corresponding antibodies, propelling BioInvent's clinical pipeline and creating lucrative licensing and partnership opportunities.

BioInvent's business model includes generating revenue through research collaborations and licensing deals with leading pharmaceutical companies, as well as manufacturing antibodies for third parties from their integrated production facility. The company continues to advance its scientific and clinical endeavors, contributing to the broader field of cancer immunotherapy.